erlotinib hydrochloride has been researched along with dacarbazine in 17 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (dacarbazine) | Trials (dacarbazine) | Recent Studies (post-2010) (dacarbazine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7,556 | 1,463 | 3,429 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | dacarbazine (IC50) |
|---|---|---|---|
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.556 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
| Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK | 1 |
3 review(s) available for erlotinib hydrochloride and dacarbazine
| Article | Year |
|---|---|
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
11 trial(s) available for erlotinib hydrochloride and dacarbazine
| Article | Year |
|---|---|
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2016 |
3 other study(ies) available for erlotinib hydrochloride and dacarbazine
| Article | Year |
|---|---|
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |